You can buy or sell ORMP and other stocks, options, ETFs, and crypto commission-free!
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Read More The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in Jerusalem, Israel.
52 Week High
52 Week Low
Research And Development
Simply Wall StFeb 27
Do Insiders Own Shares In Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)?
The big shareholder groups in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Warren Buffett said that he likes ‘a business with enduring competitive advantages that is run by able and owner-oriented people’. So it’s nice to see some insider ownership, because it may suggest that management is owner-oriented. Oramed Pharmaceuticals is a sm...
Stock Price, News, & Analysis for Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. It is also developing a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security...
PR NewswireFeb 13
Frost & Sullivan Publishes Q1 2019 Update on Oramed Pharmaceuticals Inc.
TEL AVIV, Israel, Feb 13, 2019 /PRNewswire/ -- The TASE analysis project was launched in 2016 in order to raise investor awareness to TASE listed technology and life-science companies and the markets in which these companies operate, thus creating appropriate pricing and increasing the exposure of investors from Israel and abroad.
-$0.24 per share
Expected Mar 26, Pre-Market